<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154192</url>
  </required_header>
  <id_info>
    <org_study_id>081696</org_study_id>
    <nct_id>NCT01154192</nct_id>
  </id_info>
  <brief_title>Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)</brief_title>
  <official_title>Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In women with polycystic ovary syndrome (PCOS), the cardinal physiological abnormality is
      excessive ovarian androgen production marked by increased serum testosterone (T) and
      androstenedione (A) levels. Studies to determine the alteration in ovarian steroidogenesis
      that lead to abnormal production of ovarian androgens have revealed increased CYP17 gene
      expression with accentuated 17-hydroxylase activity leading to exaggerated
      17-hydroxyprogesterone (17P) responses to luteinizing hormone (LH) stimulation. In contrast,
      T and A responses did not distinguish between PCOS and normal women, although these androgens
      were clearly greater in the former compared to the latter group. As a result, 17P
      responsiveness has been employed to determine the functional capacity of the ovary to produce
      androgens. The stimulatory agents that have been used included GnRH agonist, Lupron, at a
      dose of 10 microgram per kilogram, or hCG at a dose of 10,000 IU. The investigators propose
      to conduct a study that will determine the pattern of androgen responsiveness to 25ucg of hCG
      after 24 hours in adolescents with PCOS, those with oligomenorrhea, and in normal controls.
      This will allow for a comparison of these adolescents' ovarian functional capacity to produce
      androgens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In women with polycystic ovary syndrome (PCOS), the cardinal physiological abnormality is
      excessive ovarian androgen production marked by increased serum testosterone (T) and
      androstenedione (A) levels. Studies to determine the alteration in ovarian steroidogenesis
      that lead to abnormal production of ovarian androgens have revealed increased CYP17 gene
      expression with accentuated 17-hydroxylase activity leading to exaggerated
      17-hydroxyprogesterone (17P) responses to luteinizing hormone (LH) stimulation. In contrast,
      T and A responses did not distinguish between PCOS and normal women, although these androgens
      were clearly greater in the former compared to the latter group. As a result, 17P
      responsiveness has been employed to determine the functional capacity of the ovary to produce
      androgens. The stimulatory agents that have been used included GnRH agonist, Lupron, at a
      dose of 10 microgram per kilogram, or hCG at a dose of 10,000 IU.We propose to conduct a
      study that will determine the pattern of androgen responsiveness to 25ucg of hCG after 24
      hours in adolescents with PCOS, those with oligomenorrhea, and in normal controls. This will
      allow for a comparison of these adolescents' ovarian functional capacity to produce
      androgens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>17OHP Levels After hCG</measure>
    <time_frame>24 hours</time_frame>
    <description>Assess serum levels of 17OHP after stimulation with recombinant hCG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testosterone</measure>
    <time_frame>24 hours</time_frame>
    <description>Assess seruim levels of testosterone after stimulation with recombinant hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androstenedione</measure>
    <time_frame>24 hours</time_frame>
    <description>Assess serum levels of androstenedione after stimaultion with recombinant hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DHEA</measure>
    <time_frame>24 hours</time_frame>
    <description>Assess serum levels of DHEA after stimulation with recombinant hCG</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>PCOS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oligomenorrhea group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Each subject in the Oligomenorrhea group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.</description>
    <arm_group_label>Normal group</arm_group_label>
    <arm_group_label>Oligomenorrhea group</arm_group_label>
    <arm_group_label>PCOS group</arm_group_label>
    <other_name>recombinant human chorionic gonadotropin (r-hCG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human chorionic gonadotropin (r-hCG)</intervention_name>
    <description>Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.</description>
    <arm_group_label>Normal group</arm_group_label>
    <arm_group_label>Oligomenorrhea group</arm_group_label>
    <arm_group_label>PCOS group</arm_group_label>
    <other_name>Ovidrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal CBC (Hemoglobin must be at least 11mg/dl)

          -  Normal renal and liver function tests

          -  Normal vital signs including normal blood pressure

        Exclusion Criteria:

          -  Pregnancy

          -  On oral contraceptives

          -  On insulin lowering drugs

          -  On anti-androgens (i.e., spironolactone, flutamide, finasteride, etc)

          -  On medications that will influence androgen metabolism or clearance

          -  On medications that will inhibit the cytochrome P450 enzyme system (Cimetidine,
             ketoconazole, etc)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Jeffery Chang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD School of Medicine</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <results_first_submitted>March 29, 2019</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Jeffrey Chang, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>oligomenorrhea</keyword>
  <keyword>irregular menses</keyword>
  <keyword>hyperandrogenemia</keyword>
  <keyword>elevated testosterone</keyword>
  <keyword>adolescents</keyword>
  <keyword>androgens</keyword>
  <keyword>ovary</keyword>
  <keyword>LH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PCOS Group</title>
          <description>Intervention: Each subject in the PCOS group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
Dexamethasone: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
recombinant human chorionic gonadotropin (r-hCG): Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection</description>
        </group>
        <group group_id="P2">
          <title>Normal Group</title>
          <description>Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
Dexamethasone</description>
        </group>
        <group group_id="P3">
          <title>There Were Only 2 Groups: PCOS and Normal Subjects</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Oligpomenorrhea subjects not part of study</population>
      <group_list>
        <group group_id="B1">
          <title>PCOS Group</title>
          <description>Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.</description>
        </group>
        <group group_id="B2">
          <title>Normal Group</title>
          <description>Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.</description>
        </group>
        <group group_id="B3">
          <title>Oligomenorrhea Group</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.9" spread="1.0"/>
                    <measurement group_id="B2" value="15.4" spread="1.2"/>
                    <measurement group_id="B4" value="15.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>17OHP Levels After hCG</title>
        <description>Assess serum levels of 17OHP after stimulation with recombinant hCG</description>
        <time_frame>24 hours</time_frame>
        <population>Oligmenorhea group not included in study</population>
        <group_list>
          <group group_id="O1">
            <title>PCOS Group</title>
            <description>Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.</description>
          </group>
          <group group_id="O2">
            <title>Normal Group</title>
            <description>Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.</description>
          </group>
          <group group_id="O3">
            <title>Oligomenorrhea Group</title>
          </group>
        </group_list>
        <measure>
          <title>17OHP Levels After hCG</title>
          <description>Assess serum levels of 17OHP after stimulation with recombinant hCG</description>
          <population>Oligmenorhea group not included in study</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.5"/>
                    <measurement group_id="O2" value="1.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Testosterone</title>
        <description>Assess seruim levels of testosterone after stimulation with recombinant hCG</description>
        <time_frame>24 hours</time_frame>
        <population>Oligpmenrreha group not included in study</population>
        <group_list>
          <group group_id="O1">
            <title>PCOS Group</title>
            <description>Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.</description>
          </group>
          <group group_id="O2">
            <title>Normal Group</title>
            <description>Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
.</description>
          </group>
          <group group_id="O3">
            <title>Oligomenorrhea Group</title>
          </group>
        </group_list>
        <measure>
          <title>Testosterone</title>
          <description>Assess seruim levels of testosterone after stimulation with recombinant hCG</description>
          <population>Oligpmenrreha group not included in study</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                    <measurement group_id="O2" value="1.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Androstenedione</title>
        <description>Assess serum levels of androstenedione after stimaultion with recombinant hCG</description>
        <time_frame>24 hours</time_frame>
        <population>Oligomenorreha group not inlcuded in study</population>
        <group_list>
          <group group_id="O1">
            <title>PCOS Group</title>
            <description>Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.</description>
          </group>
          <group group_id="O2">
            <title>Normal Group</title>
            <description>Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.</description>
          </group>
          <group group_id="O3">
            <title>Oligomenorrhea Group</title>
          </group>
        </group_list>
        <measure>
          <title>Androstenedione</title>
          <description>Assess serum levels of androstenedione after stimaultion with recombinant hCG</description>
          <population>Oligomenorreha group not inlcuded in study</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DHEA</title>
        <description>Assess serum levels of DHEA after stimulation with recombinant hCG</description>
        <time_frame>24 hours</time_frame>
        <population>Oligomenrrhea group not included in study</population>
        <group_list>
          <group group_id="O1">
            <title>PCOS Group</title>
            <description>Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.</description>
          </group>
          <group group_id="O2">
            <title>Normal Group</title>
            <description>Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.</description>
          </group>
          <group group_id="O3">
            <title>Oligomenorrhea Group</title>
          </group>
        </group_list>
        <measure>
          <title>DHEA</title>
          <description>Assess serum levels of DHEA after stimulation with recombinant hCG</description>
          <population>Oligomenrrhea group not included in study</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                    <measurement group_id="O2" value="1.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>The number of participants at risk for Other Adverse Events, All-Cause Mortality, and Serious Adverse Events should be 24</desc>
      <group_list>
        <group group_id="E1">
          <title>PCOS Group</title>
          <description>Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.</description>
        </group>
        <group group_id="E2">
          <title>Normal Group</title>
          <description>Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.</description>
        </group>
        <group group_id="E3">
          <title>Oligomenorrhea Group</title>
          <description>Not included in the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. R. Jeffrey Chang</name_or_title>
      <organization>UC San Diego School of Medicine</organization>
      <phone>858-534-8930</phone>
      <email>rjchang@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

